Form 4: Beam Therapeutics CEO Sells Shares Under 10b5-1 Plan

Beam Therapeutics CEO John M. Evans reports transactions involving the exercise of stock options and sale of common stock, executed under a pre-arranged trading plan.

Summary

• John M. Evans, CEO of Beam Therapeutics Inc., reported several transactions on June 29th and June 30th, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of common stock.
• All sales were conducted under a Rule 10b5-1 trading plan adopted on May 16, 2025, which is designed to satisfy affirmative defense conditions.
• A total of 18,663 shares were acquired via option exercise at $0.67 and 6,337 shares at $1.03 on June 29th.
• On the same day, 13,421 shares were sold at a weighted average of $35.1336 and 11,579 shares at $35.9119.
• On June 30th, 25,000 shares were acquired via option exercise at $1.03.
• Also on June 30th, 23,100 shares were sold at a weighted average of $34.2633 and 1,900 shares at $34.8437.
• Following these transactions, the reporting person beneficially owns 1,047,205 shares of common stock directly.
• An additional 103,000 shares are held indirectly through the John M. Evans, III 2018 Irrevocable Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While significant share sales by the CEO can be a concern, the execution under a pre-established 10b5-1 plan mitigates concerns about opportunistic trading.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive sales.
• The CEO continues to hold a significant number of shares (1,047,205 directly and 103,000 indirectly) after the reported sales.

Negatives

• The CEO sold a substantial number of shares (25,000 shares on June 30th and 13,421 + 11,579 = 25,000 shares on June 29th) which could be perceived negatively by the market.
• The sales occurred at prices significantly higher than the exercise prices of the stock options, indicating a profitable exit for the sold shares.

Risks

• The sale of a large number of shares by a key executive could be interpreted as a lack of confidence in the company's near-term prospects, potentially impacting share price.
• The weighted average pricing for sales indicates a range of prices, and the specific details of each transaction within that range are not fully disclosed in this summary format.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It is a report of past transactions.

Management Comments

• The Reporting Person undertakes to provide to Beam Therapeutics Inc. ('BEAM'), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that insider selling, especially under a 10b5-1 plan, is a common occurrence for executives looking to diversify or manage personal finances. However, the volume and timing relative to company news can influence market perception.

Stakeholder Impact

• Shareholders: May view the CEO's sale of shares with caution, potentially leading to short-term stock price pressure, although the 10b5-1 plan provides some reassurance.
• Employees: May be influenced by the CEO's actions, though the structured nature of the sales is intended to minimize negative signaling.
• Management: The CEO's actions are subject to scrutiny, and adherence to the 10b5-1 plan is crucial for maintaining governance standards.

Next Steps

• The reporting person may continue to execute transactions under the Rule 10b5-1 plan.
• The company may be required to provide further transaction details upon request from the SEC or security holders.

Key Dates

Recommendation

The filing reports routine insider sales under a pre-arranged plan, which is not typically a strong indicator for a buy or sell recommendation. The continued holding of a substantial number of shares by the CEO suggests a baseline confidence, warranting a 'hold' position pending other company-specific developments.

Keywords

Beam Therapeutics, BEAM, Form 4, Insider Trading, Stock Options, Rule 10b5-1, SEC Filing, Executive Sales, Beneficial Ownership, Common Stock